<DOC>
	<DOCNO>NCT02683421</DOCNO>
	<brief_summary>Determine localization Tc 99m tilmanocept SPECT SPECT/CT image subject active RA concordance clinical symptomology .</brief_summary>
	<brief_title>Evaluation SC Injected Tc 99m Tilmanocept Localization Active RA Subjects SPECT SPECT/CT Imaging</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>The subject provide write informed consent HIPPA authorization initiation studyrelated procedure . CONTROLS : The subject 2145 year age time consent . The subject experience joint pain least 4 week prior consent date deem clinically free inflammatory disease ( ) . ACTIVE RHEUMATOID ARTHRITIS The subject least 21 year age time consent . The subject moderate severe RA , base either 1987American College Rheumatology ( ACR ) score ≥ 4/7 2010 ACR/EULAR score ≥ 6/10 . The subject DAS28 &gt; 4.4 ( use ESR ) . If subject methotrexate , stable dose &gt; 4 week prior screen visit . If subject biologic therapy , stable dose &gt; 8 week prior screen visit . If subject NASIDS oral corticosteroid , ≤ 10mgmg/day equivalent , stable dose &gt; 4 week prior screen visit . The subject pregnant lactating . BMI &gt; 32.0 . The subject currently receive chemotherapy noninflammatory relate condition radiation therapy . Chronic persistent infection condition would , opinion examine physician , preclude participation . The subject know allergy reaction dextran exposure . The subject receive investigational product within 30 day prior Tc99m tilmanocept administration . The subject receive radiopharmaceutical within 7 radioactive halflives radiopharmaceutical prior administration Tc 99m tilmanocept .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>tilmanocept</keyword>
	<keyword>image</keyword>
</DOC>